Masahiro Asaka

Dr. Masahiro Asaka


Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2016 in Gut
Verified
Journal Article
Open access
PDF file
KMKazunari Murakami
Kazunari Murakami
YSYuuichi Sakurai
Yuuichi Sakurai
MSMadoka Shiino
Madoka Shiino
NFNobuo Funao
Nobuo Funao
ANAkira Nishimura
Akira Nishimura
MAMasahiro Asaka
Masahiro Asaka
Objective: The objective of this study was to assess the efficacy, safety and tolerability of vonoprazan, a novel potassium-competitive acid blocker, as a component of Helicobacter pylori eradication therapy. Design: A randomised, double-blind, multicentre, parallel-group study was conducted to verify the non-inferiority of vonoprazan 20 mg to lansoprazole 30 mg as part of first-line triple therapy (with amoxicillin 750 mg and clarithromycin 200 or 400 mg) in H pylori- positive patients with gastric or duodenal ulcer history. The first 50 patients failing first-line therapy with good compliance also received second-line vonoprazan-based triple therapy (with amoxicillin 750 mg and metronidazole 250 mg) as an open-label treatment. Results: Of the 650 subjects randomly allocated to either first-line triple therapy, 641 subjects completed first-line therapy and 50 subjects completed second-line therapy. The first-line eradication rate (primary end point) was 92.6% (95% CI 89.2% to 95.2%) with vonoprazan versus 75.9% (95% CI 70.9% to 80.5%) with lansoprazole, with the difference being 16.7% (95% CI 11.2% to 22.1%) in favour of vonoprazan, thus confirming the non-inferiority of vonoprazan (p<0.0001). The second-line eradication rate (secondary end point) was also high (98.0%; 95% CI 89.4% to 99.9%) in those who received second-line therapy (n=50). Both first-line triple therapies were well tolerated with no notable differences. Second-line triple therapy was also well tolerated. Conclusion: Vonoprazan is effective as part of first-line triple therapy and as part of second-line triple therapy in H pylori- positive patients with a history of gastric or duodenal ulcer. Trial registration number: NCT01505127.

13 January 2010 in Helicobacter
Verified
Journal Article
Closed access
PDF file
MAMasahiro Asaka
Masahiro Asaka
MKMototsugu Kato
Mototsugu Kato
STShin‐Ichi Takahashi
Shin‐Ichi Takahashi
YFYoshihiro Fukuda
Yoshihiro Fukuda
TSToshiro Sugiyama
Toshiro Sugiyama
KSKentaro Sugano
Kentaro Sugano

1 March 2003 in Hepatology
Verified
Journal Article
Open access
PDF file
YYYoshiya Yamamoto
Yoshiya Yamamoto
MSMichiie Sakamoto
Michiie Sakamoto
GFGen Fujii
Gen Fujii
HTHitomi Tsuiji
Hitomi Tsuiji
KKKengo Kenetaka
Kengo Kenetaka
SHSetsuo Hirohashi
Setsuo Hirohashi
To identify the genes responsible for carcinogenesis and progression of hepatocellular carcinoma (HCC), we screened differentially expressed genes in several human HCC cell lines. Among these genes, Gpr49 was up–regulated in PLC/PRF/5 and HepG2. Gpr49 is a member of the glycoprotein hormone receptor subfamily, which includes the thyroid–stimulating hormone receptor (TSHR). However, Gpr49 remains to be an orphan G–protein–coupled receptor. By real–time quantitative reverse transcriptase polymerase chain reaction (RT–PCR) analysis, overexpression (>3–fold increase compared with the corresponding noncancerous liver tissue) of Gpr49 mRNA was observed in 18 of 38 (47%) HCCs compared with corresponding noncancerous livers. Clinicopathologically, overexpression of Gpr49 was frequently observed in HCC with mutation in β–catenin exon 3 (14 of 16 cases, 87.5%). Moreover, introduction of mutant β–catenin into mouse hepatocytes in culture caused up–regulation of the Gpr49 mouse homologue. Therefore, Gpr49 is likely to be a target gene activated by Wnt–signaling in HCC. In conclusion, although much is still unknown, Gpr49 may be critically involved in the development of HCCs with β–catenin mutations and has the potential to be a new therapeutic target in the treatment of HCC.

27 October 2013 in Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
MAMasahiro Asaka
Masahiro Asaka
MKMototsugu Kato
Mototsugu Kato
NSNaoya Sakamoto
Naoya Sakamoto
In Japan, the annual number of deaths from gastric cancer is approximately 50,000 and there has been no change over the last 50 years. So far, all efforts have been directed toward improving the detection of early gastric cancer by barium X-ray and endoscopy, since early cancer has a good prognosis, resulting in Japan having the best diagnostic capability for early gastric cancer worldwide. The 5-year survival rate of gastric cancer patients exceeds 60 % in Japan and is much higher than that in Europe and the US (20 %) because of this superior diagnosis of early gastric cancer. In February 2013, national health insurance coverage for Helicobacter pylori eradication therapy to treat H. pylori-associated chronic gastritis became available in Japan. H. pylori-associated gastritis leads to development of gastric and duodenal ulcers and gastric polyps. Therefore, providing treatment for gastritis is likely to substantially decrease the prevalence of both gastric and duodenal ulcers and polyps. Because treatment for H. pylori-associated gastritis, which leads to atrophic gastritis and gastric cancer, is now covered by health insurance in Japan, a strategy to eliminate gastric cancer-related deaths by taking advantage of this innovation was planned. According to this strategy, patients with gastritis will be investigated for H. pylori infection and those who are positive will receive eradication therapy followed by periodic surveillance. If this strategy is implemented, deaths from gastric cancer in Japan will decrease dramatically after 10–20 years.

3 August 2017 in Helicobacter
Verified
Journal Article
Open access
PDF file
MTMomoko Tsuda
Momoko Tsuda
MAMasahiro Asaka
Masahiro Asaka
MKMototsugu Kato
Mototsugu Kato
RMRumiko Matsushima
Rumiko Matsushima
KFKenji Fujimori
Kenji Fujimori
NSNaoya Sakamoto
Naoya Sakamoto
Background: In Japan, there have been approximately 50 000 deaths from gastric cancer annually for over 40 years with little variation. It has been reported that most gastric cancers in Japan are caused by Helicobacter pylori infection. H. pylori eradication therapy was approved for patients with chronic gastritis by the Japanese national health insurance scheme in February 2013 for patients with an endoscopic diagnosis of chronic gastritis is positive for H. pylori. We examined the effect on gastric cancer death rate 4 years after expansion of health insurance coverage.Aim: We conducted an epidemiological study and analyzed trends in prescription for H. pylori eradication therapy. We used the electronic medical claims database from Hokkaido, Japan to evaluate the impact of expansion of national health insurance coverage for H. pylori eradication therapy on deaths from gastric cancer.Methods: Data on deaths from gastric cancer were obtained from the Japanese Ministry of Health, Labour and Welfare and the Cancer Statistics in Japan (2015). Analysis of electronic claims records was performed using the National Database, mainly focusing on Hokkaido. Prescriptions for H. pylori eradication therapy and the number of patients treated for gastric cancer were also extracted from the Hokkaido database.Results: Approximately 1.5 million prescriptions for H. pylori eradication therapy were written annually. Gastric cancer deaths fell each year: 48 427 in 2013, 47 903 in 2014, 46 659 in 2015, and 45 509 in 2016, showing a significant decrease after expansion of insurance coverage for H. pylori eradication therapy (P<.0001).Conclusions: Prescriptions for H. pylori eradication therapy increased markedly after approval of the gastritis indication by the national health insurance scheme and was associated with a significant decrease in gastric cancer deaths.

26 November 2012 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
MAMasahiro Asaka
Masahiro Asaka
We explore a strategy for the elimination of gastric cancer deaths in Japan. Most gastric cancer is due to H. pylori infection in Japan. The effect of H. pylori eradication therapy on gastric cancer prevention in younger people is excellent, but it declines along with advancing age. Therefore, a test‐and‐treat approach to H. pylori infection is recommended in younger people, while for people aged 50 years or older a combination of countermeasures for H. pylori eradication that includes primary prevention and secondary prevention by endoscopic examination will reduce gastric cancer deaths, since this method will increase early detection if the disease occurs. In this paper, I described a new strategy of elimination of gastric cancer deaths in Japan due to such a high quality of diagnosis and treatment for gastric cancer. If this strategy succeeds, the incidence of gastric cancer in Japan may decrease much longer than 10 years.